1. N -Methyl Costaricine and Costaricine, Two Potent Butyrylcholinesterase Inhibitors from Alseodaphne pendulifolia Gamb.
- Author
-
Husna Hasnan MH, Sivasothy Y, Khaw KY, Nafiah MA, Hazni H, Litaudon M, Wan Ruzali WA, Liew SY, and Awang K
- Subjects
- Cholinesterase Inhibitors pharmacology, Cholinesterase Inhibitors therapeutic use, Cholinesterase Inhibitors chemistry, Butyrylcholinesterase metabolism, Plant Extracts pharmacology, Plant Extracts chemistry, Acetylcholinesterase metabolism, Alkaloids pharmacology, Alkaloids chemistry, Benzylisoquinolines, Lauraceae chemistry
- Abstract
Studies have been conducted over the last decade to identify secondary metabolites from plants, in particular those from the class of alkaloids, for the development of new anti-Alzheimer's disease (AD) drugs. The genus Alseodaphne , comprising a wide range of alkaloids, is a promising source for the discovery of new cholinesterase inhibitors, the first-line treatment for AD. With regard to this, a phytochemical investigation of the dichloromethane extract of the bark of A. pendulifolia Gamb. was conducted. Repeated column chromatography and preparative thin-layer chromatography led to the isolation of a new bisbenzylisoquinoline alkaloid, N -methyl costaricine ( 1 ), together with costaricine ( 2 ), hernagine ( 3 ), N -methyl hernagine ( 4 ), corydine ( 5 ), and oxohernagine ( 6 ). Their structures were elucidated by the 1D- and 2D-NMR techniques and LCMS-IT-TOF analysis. Compounds 1 and 2 were more-potent BChE inhibitors than galantamine with IC
50 values of 3.51 ± 0.80 µM and 2.90 ± 0.56 µM, respectively. The Lineweaver-Burk plots of compounds 1 and 2 indicated they were mixed-mode inhibitors. Compounds 1 and 2 have the potential to be employed as lead compounds for the development of new drugs or medicinal supplements to treat AD.- Published
- 2023
- Full Text
- View/download PDF